Definium Therapeutics DFTX
NASDAQ DFTX
$38.31 +0.31 (+0.82%)
As of: Sep 4, 2026 · 3:12 PM EDT

Definium Therapeutics (DFTX) Non Operating Interest Expenses (2023 - 2026)

Analysis

Definium Therapeutics (DFTX) Non Operating Interest Expenses (2023 - 2026) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non Operating Interest Expenses (Qtr)
1 Vertex Pharmaceuticals 138.58 Bn 130.73 Bn 2.84 Bn -
2 Regeneron Pharmaceuticals 85.33 Bn 77.33 Bn 3.93 Bn 11.00 Mn
3 Argenx Se 63.43 Bn 58.24 Bn 1.37 Bn -1.00 Mn
4 Moderna 57.84 Bn 52.70 Bn 52.00 Mn -
5 Revolution Medicines 44.01 Bn 44.01 Bn - 23.78 Mn
6 BeOne Medicines 39.93 Bn 34.83 Bn 1.53 Bn 39.74 Mn
7 Alnylam Pharmaceuticals 35.47 Bn 32.16 Bn 992.69 Mn 82.05 Mn
8 Royalty Pharma 28.39 Bn 27.56 Bn - 93.62 Mn
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn 20.27 Mn
10 Definium Therapeutics 4.24 Bn 4.24 Bn - 1.23 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 1.23 Mn
Mar 31, 2026 1.25 Mn
Dec 31, 2025 1.29 Mn
Sep 30, 2025 1.30 Mn
Jun 30, 2025 2.34 Mn
Mar 31, 2025 602,000.00
Dec 31, 2024 656,000.00
Sep 30, 2024 727,000.00
Jun 30, 2024 466,000.00
Mar 31, 2024 434,000.00
Dec 31, 2023 439,000.00
Sep 30, 2023 328,000.00
Jun 30, 2023 77,000.00
Mar 31, 2023 76,000.00